Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Aegis Therapeutics, Dauntless Pharmaceuticals deal

    Aegis Therapeutics LLC, San Diego, Calif. Dauntless Pharmaceuticals Inc., San Diego, Calif. Business: Cancer, Drug delivery Aegis granted Dauntless exclusive, worldwide rights to use its Intravail drug delivery …

    Published on 8/24/2015
  • Affymetrix, Cytox deal

    Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif. Cytox Ltd., Birmingham, U.K. Business: Diagnostic Cytox and Affymetrix partnered to develop and commercialize a blood-based genetic assay for Alzheimers disease (AD) …

    Published on 8/24/2015
  • Aveo Pharmaceuticals, Novartis deal

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Endocrine/Metabolic Aveo granted Novartis exclusive, worldwide rights to develop and commercialize …

    Published on 8/24/2015
  • Bayer, Vipergen deal

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Vipergen ApS, Copenhagen, Denmark Business: High throughput screening Vipergen will use its high fidelity DNA-encoded library platform to identify small molecules against …

    Published on 8/24/2015
  • Bio-Reference Laboratories, Opko deal

    Bio-Reference Laboratories Inc., Elmwood Park, N.J. Opko Health Inc. (NYSE:OPK;Tel Aviv:OPK), Miami, Fla. Business: Supply/Service Opko completed its acquisition of clinical service laboratory Bio-Reference. Bio-…

    Published on 8/24/2015
  • Bristol-Myers, Medical University of South Carolina deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Medical University of South Carolina, Charleston, S.C. Business: Autoimmune, Pulmonary, Renal Bristol-Myers and MUSC partnered to conduct translational research on …

    Published on 8/24/2015
  • Catalyst Biosciences, Targacept deal

    Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Targacept Inc., Winston-Salem, N.C. Business: Hematology, Gastrointestinal Catalyst completed its merger with Targacept to form new company Catalyst …

    Published on 8/24/2015
  • City of Hope, Novonco Therapeutics deal

    City of Hope, Duarte, Calif. Novonco Therapeutics Inc., Los Angeles, Calif. Business: Cancer City of Hope granted Novonco exclusive rights to COH29. The small molecule ribonucleotide reductase inhibitor is in …

    Published on 8/24/2015
  • Cristal Therapeutics, PX Biosolutions deal

    Cristal Therapeutics, Maastricht, the Netherlands PX Biosolutions Pty. Ltd., South Melbourne, Australia Business: Cancer The companies will combine Cristals CriVac technology and PXs DCtag vaccine formulation to develop…

    Published on 8/24/2015
  • Eisai, JCR Pharmaceuticals deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan JCR Pharmaceuticals Co. Ltd. (Tokyo:4552), Ashiya, Japan Business: Neurology, Drug delivery The companies will jointly conduct research applying JCRs J-Brain Cargo blood-brain …

    Published on 8/24/2015
  • Ember Therapeutics, Knight Therapeutics deal

    Ember Therapeutics Inc., Watertown, Mass. Knight Therapeutics Inc. (TSX:GUD), Westmount, Quebec Business: Autoimmune Ember granted Knight exclusive rights to commercialize Embers bone morphogenetic protein 7 (BMP7; OP-1…

    Published on 8/24/2015
  • Faulk Pharmaceuticals, Panther Biotechnology deal

    Faulk Pharmaceuticals Inc., Raleigh, N.C. Panther Biotechnology Inc. (OTCQB:PBYA), Evanston, Ill. Business: Cancer, Drug delivery Panther completed the acquisition of Faulks pharmaceutical assets for 50,000 Panther …

    Published on 8/24/2015
  • Ferring, Intralytix deal

    Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Intralytix Inc., Baltimore, Md. Business: Autoimmune The companies partnered to develop bacteriophage therapies for inflammatory bowel disease (IBD). Intralytix will …

    Published on 8/24/2015
  • Formula Pharmaceuticals, Max Delbrueck Center for Molecular Medicine Berlin-Buch deal

    Formula Pharmaceuticals Inc., Berwyn, Pa. Max Delbrueck Center for Molecular Medicine Berlin-Buch, Berlin, Germany Business: Autoimmune, Cancer Formula and the center partnered to develop cytokine-induced killer (CIK) …

    Published on 8/24/2015
  • HiFiBiO, Pfizer deal

    HiFiBiO S.A.S., Paris, France Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Antibodies HiFiBiO received an undisclosed milestone payment from Pfizer under a 2014 deal to validate HiFiBiOs high throughput antibody …

    Published on 8/24/2015
  • Hutchison China, J&J deal

    Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune, Inflammation Johnson & Johnsons Janssen Pharmaceuticals Inc. unit terminated a 2008 deal …

    Published on 8/24/2015
  • J&J, Forge Therapeutics deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Forge Therapeutics Inc., San Diego, Calif. Business: Chemistry Forge partnered with Johnson & Johnsons Janssen Research & Development LLC unit to discover small molecule…

    Published on 8/24/2015
  • Ligand, Sanofi deal

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer Ligand granted Sanofi exclusive, worldwide rights to use Captisol sulfobutylether beta-…

    Published on 8/24/2015
  • New Zealand Pharmaceuticals, Fortress Biotech deal

    New Zealand Pharmaceuticals Ltd., Palmerston North, New Zealand Fortress Biotech Inc. (NASDAQ:FBIO), New York, N.Y. Business: Musculoskeletal, Renal New Zealand granted Fortress Altamira Bio subsidiary exclusive, …

    Published on 8/24/2015
  • Sprout Pharmaceuticals, Valeant Pharmaceuticals deal

    Sprout Pharmaceuticals Inc., Raleigh, N.C. Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Business: Genitourinary Valeant will acquire Sprout for $1 billion in cash. Last week, FDA approved…

    Published on 8/24/2015
  • Telesta, BL&H deal

    Telesta Therapeutics Inc. (TSX:TST;Pink:BNHLF), Belleville, Ontario BL&H Co. Ltd., Seoul, South Korea Business: Cancer Telesta granted BL&H exclusive rights to commercialize MCNA in South Korea. In June, Telesta …

    Published on 8/24/2015
  • TeOra Health, Aequus Pharmaceuticals deal

    TeOra Health Ltd., Penticton, B.C. Aequus Pharmaceuticals Inc. (TSX-V:AQS), Vancouver, B.C. Business: Cancer, Ophthalmic Aequus will acquire specialty pharmaceutical company TeOra in a stock deal for 3.4 million shares …

    Published on 8/24/2015
  • TeOra Health, Aequus Pharmaceuticals deal

    TeOra Health Ltd., Penticton, B.C. Aequus Pharmaceuticals Inc. (TSX-V:AQS), Vancouver, B.C. Business: Cancer, Transplant, Ophthalmic Aequus acquired specialty pharmaceutical company TeOra for 420,000 shares of Aequus, …

    Published on 8/24/2015
  • Volution, Celsus Therapeutics deal

    Volution Immuno Pharmaceuticals S.A., Geneva, Switzerland Celsus Therapeutics plc (NASDAQ:CLTX), London, U.K. Business: Neurology, Hematology Celsus will merge with Volution in a stock transaction, with the newco to be …

    Published on 8/24/2015
  • WuXi PharmaTech, New WuXi deal

    WuXi PharmaTech Inc. (NYSE:WX), Shanghai, China New WuXi Life Science Ltd., Shanghai, China Business: Supply/Service WuXi has agreed to be acquired and taken private by Chairman and CEO Ge Li and an investor group for $…

    Published on 8/24/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993